Also, Costa et al. 2021 reported in preclinical models of different solid tumors, such as HCC and MM patients, that the resistance to the anti-PD-1/PD-L1 antibody is convoy by CD38 up-regulation, which mediates its immune-suppression effect via enhancing extracellular ADO11. The gene discussed is CD38; the disease is Miyoshi myopathy.